CD19/CD22-targeting CAR-T Cells therapy(Prekin Biopharmaceutical)

N/A

Report date: 2026/04/08 15:41:59

Base Information

Drug NameCD19/CD22-targeting CAR-T Cells therapy(Prekin Biopharmaceutical)
Drug Alias NamePRG2302PRG-2302
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Pregene Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A